Predictive Value of Two Polymorphisms of ERCC2, rs13181 and rs1799793, in Clinical Outcomes of Chemotherapy in Gastric Cancer Patients: A Meta-Analysis

Table 4

Meta-analysis of the association between ERCC2 rs1799793 polymorphism and chemotherapy in objective response rate and overall survival for gastric cancer patients.

Genetic comparisons	Subgroup analysis	No. of studies	Test of association			Model	Test of heterogeneity
			OR/HR (95% CI)					(%)
Objective response rate (ORR)
AA vs. GG	Total ethnicity	8	1.17 (0.70–1.95)	0.59	0.556	R	0.002	69.2	0.348
	Caucasian	2	1.70 (0.71–4.05)	1.19	0.234	R	0.080	67.4
	Asian	6	0.98 (0.48–1.98)	0.06	0.950	R	0.002	74.1
GA vs. GG	Total ethnicity	9	0.94 (0.69–1.27)	0.41	0.679	R	0.012	59.1	0.259
	Caucasian	2	0.88 (0.23–3.38)	0.19	0.805	R	0.003	89.0
	Asian	7	1.01 (0.82–1.24)	0.06	0.955	F	0.299	17.2
AA + GA vs. GG	Total ethnicity	10	1.12 (0.85–1.46)	0.79	0.429	R	0.001	68.9	0.661
	Caucasian	2	1.15 (0.39–3.42)	0.26	0.797	R	0.009	85.5
	Asian	8	1.13 (0.86–1.49)	0.87	0.384	R	0.006	64.8
AA vs. GG + GA	Total ethnicity	8	1.24 (0.81–1.92)	0.98	0.325	R	0.009	62.6	0.053
	Caucasian	2	1.79 (1.24–2.57)	3.13	0.002	F	0.794	0
	Asian	6	1.02 (0.54–1.90)	0.05	0.962	R	0.006	69.2
Overall survival (HR)
GA vs. GG	Asian	8	1.20 (0.96–1.51)	1.61	0.108	F	0.577	0	0.900
AA vs. GG	Asian	6	1.77 (1.20–2.60)	2.89	0.004	F	0.227	27.7	0.959
GA + AA vs. GG	Asian	4	1.62 (1.26–2.09)	3.76	<0.001	F	0.479	0	0.032

OR: odds ratio; HR: hazard ratio; CI: confidence interval; vs.: versus; F: fixed effect model; R: random effect model.